Dermatology for Practice, 2020, issue 1

Editorial

Alkohol včera, dnes – a zítra?

doc. MUDr. Michal Hladík, Ph.D.

Dermatol. praxi. 2020;14(1):3  

Review articles

Assessment of atopic eczema severity with EASI

MUDr. Filip Rob, Ph.D., prof. MUDr. Jana Hercogová, CSc.

Dermatol. praxi. 2020;14(1):6-8 | DOI: 10.36290/der.2020.001  

Atopic eczema is a common chronic inflammatory disease that can significantly affect a patient's quality of life. Treatment options, particularly in severe forms of the disease, have been limited for a long time and largely included broad-spectrum immunosuppressive agents, such as cyclosporine, which, however, possess potential numerous adverse effects. The first biological therapy for atopic eczema has recently become available and other new drugs will follow in the years to come. Given the economic costs of novel modern drugs, the introduction of standardized scoring systems to objectively evaluate the efficacy of these drugs is becoming necessary....

Sexually transmitted infections: a modern approach to diagnosis

MUDr. Hana Zákoucká

Dermatol. praxi. 2020;14(1):10-16 | DOI: 10.36290/der.2020.006  

Sexually transmitted infections (STIs) are very common worldwide, in Europe as well as the Czech Republic. According to WHO estimates, one million of new patients worldwide daily contract one of the STIs. A natural host of these infections is the man only. Differential diagnosis always requires laboratory testing to identify the causative agent. In order to choose a diagnostic approach, it is essential to have knowledge of the natural history of the clinical disease and of the effect of antibiotics and antiretroviral drugs, including those administered in an untargeted manner.

Peroral isotretinoin in a treatment of acne

MUDr. Zuzana Nevoralová, Ph.D.

Dermatol. praxi. 2020;14(1):19-23 | DOI: 10.36290/der.2020.007  

Acne is a polymorphic inflammatory disease of a pilosebaceous unit. Peroral isotretinoin belongs to the first non-aromatic generation of retinoids and is the most effective medicine in acne treatment. It is indicated first of all for a therapy of severe and resistent forms of acne. The therapy should by directed only by a dermatologist who is experienced in the treatment with this medicine. In the article basic only informations about an effect, indications and about the course of the treatment with peroral isotretinoin including a maintenance therapy are described.

Most commonly occurring skin infections of children in pediatric outpatient department

MUDr. Štěpánka Čapková

Dermatol. praxi. 2020;14(1):24-28  

Bacterial skin infections are some of the most commonly occurring infections of patients which visit pediatric outpatient department. It is important to have a good understanding of the common clinical manifestations and patogens involved in bacterial skin infections to be able to manage them approprietely. The classification, etiology and current management of these diseases are presented.

Photoprotection in drug‑induced photosensitivity

doc. MUDr. Karel Ettler, CSc., MUDr. Jiří Ettler

Dermatol. praxi. 2020;14(1):30-35 | DOI: 10.36290/der.2020.009  

Exposure to solar ultraviolet (UV) radiation can cause immediate or delayed harmful effects in the skin. Such effects can be amplified by topical and systemic drugs that have photosensitising potential. Drug cessation or thorough photoprotection is required. Avoiding direct sun exposure, using protective clothes and sunscreens constitute an effective photoprotection.

Case report

Mouth ulcer as a side effect of methotrexate therapy

MUDr. Lucie Zgažarová

Dermatol. praxi. 2020;14(1):36-38 | DOI: 10.36290/der.2020.002  

Following case report describes the case of the patient with two month lasting progressive lesion of the lower lip, which was histologically verified as the EBV positive mucocutaneous ulcer corresponding with long-term use of methotrexat. Mucocutaneous ulcer induced by the EBV infection is a rare clinical-pathological unit connected with imunosuppression of various etiology, here an important role has also an age-related immunosenescence. It is characterized by localy isolated cutaneous and mucosal lesion, it has indolent behavior and limited clinical course. Determination of the correct diagnosis is based on anamnestic data, clinical course and specific...

Cosmetic dermatology spot

Aesthetic facial treatments

MUDr. Kateřina Klauzová

Dermatol. praxi. 2020;14(1):43-50  

Aesthetic facial treatments have a wide range of therapeutic options. Botulinum toxin and filler applications are most common. The effect of both procedures is effective and visible. Another procedure are mesotherapy, PRP therapy, chemical peeling and thread application. Procedures requiring expensive equipment are lasers, intense pulsed light, ultrasound and radiofrequency treatment. It is recommended to combine individual therapies because of the synergistic effect for the most aesthetically pleasing result. However, this approach requires higher equipment costs.

Information and commentaries

Postřehy z 28. kongresu Evropské akademie dermatovenerologie (EADV) v Madridu, 9.-12. 10. 2019

doc. MUDr. Karel Ettler, CSc.

Dermatol. praxi. 2020;14(1):51-52  

Company information

Přínosy kožní pěny Enstilar při léčbě psoriázy u starších osob

MUDr. Zuzana Dančová

Dermatol. praxi. 2020;14(1):53-54 | DOI: 10.36290/der.2020.010  

Pharmacological profile

Guselkumab (Tremfya)

MUDr. Jan Hugo, doc. MUDr. Spyridon Gkalpakiotis, Ph.D., MBA

Dermatol. praxi. 2020;14(1):39-42 | DOI: 10.36290/der.2020.003  

As knowledge of the pathogenesis of psoriasis deepened, the crucial importance of interleukin 23 (IL-23) was recognized. This was also reflected by the development of new therapies. Guselkumab is the first approved biologic drug with specific inhibition of IL-23. Our article summarizes the therapeutic potential of this drug and recapitulates the latest information on the effect of interleukin 23.


Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.